News
3d
Zacks Investment Research on MSNBSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two ...
The Boston Globe Its stock is up 50 percent. Billion-dollar deals for breakfast. How did Boston Scientific get its mojo back? “It’s been a brick by brick, constant improvement, strengthening ...
Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals.
Hosted on MSN5mon
M&A Synergies Drive BSX: Is it Worth Buying the Stock Now? - MSNBoston Scientific stock is currently trading close to its 52-week high. In the past four trading sessions, the stock has consistently traded above $94.00 per share, closing at $95.65 yesterday.
Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX stock is a Hold.
For first-quarter 2025, Boston Scientific projects adjusted earnings in the range of 66-68 cents per share. Revenue growth is projected in the range of approximately 17-19% on a reported basis (up ...
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.
Medical-products company Boston Scientific reported third-quarter results before market open Last Updated: Oct. 23, 2024 at 7:39 a.m. ET First Published: Oct. 23, 2024 at 6:55 a.m. ET Share ...
Boston Scientific’s Relievant Medsystems used at least 80 unclaimed bodies for training, including that of a murdered 21-year-old woman whose family was fighting to bring her home. The company ...
Shares of Boston Scientific slipped 0.7% to $105.46 in early trading Wednesday, while shares of Edwards rose 1.8% to $77.60 and shares of Medtronic gained 1.1% to $82.06.
With the acquisition, Boston Scientific will pay $360 million upfront for the remaining 90% stake and up to an additional $180 million once specific regulatory milestones are met.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results